Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tandemact
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpbef5164082ea0e74f1594414cc1788ab
identifier: http://ema.europa.eu/identifier
/EU/1/06/366/006
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tandemact 30 mg/2 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-bef5164082ea0e74f1594414cc1788ab
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/06/366/006
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tandemact
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Tandemact contains pioglitazone and glimepiride which are anti-diabetic medicines, used to control blood sugar level.
It is used in adults when metformin is not suitable to treat type 2 (non-insulin dependent) diabetes mellitus. This type 2 diabetes usually develops in adulthood where the body either does not produce enough insulin (a hormone that controls blood sugar levels), or cannot effectively use the insulin it produces.
Tandemact helps control the level of sugar in your blood when you have type 2 diabetes by increasing the amount of insulin available and helping your body make better use of it. Your doctor will check whether Tandemact is working 3 to 6 months after you start taking it.
Do not take Tandemact
Warnings and precautions Talk to your doctor or pharmacist before taking Tandemact (see also section 4)
You may also experience a reduction in blood count (anaemia). Your doctor may take blood tests to monitor your blood cell levels and liver function.
Hypoglycaemia When you take Tandemact, your blood sugar could fall below the normal level (hypoglycaemia). If you experience symptoms of hypoglycaemia such as cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea, you should take some sugar to increase your blood sugar level again. Ask your doctor or pharmacist for more information if you are not sure how to recognise this. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
Broken bones A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.
Children and adolescents Use in children and adolescents under 18 years is not recommended.
Other medicines and Tandemact Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines can weaken or strengthen the effect of Tandemact on the level of sugar in your blood.
The following medicines can increase the blood sugar lowering effect of Tandemact. This can lead to a risk of hypoglycaemia (low blood sugar):
The following medicines may decrease the blood sugar lowering effect of Tandemact. This can lead to a risk of hyperglycaemia (high blood sugar level):
The following medicines can increase or decrease the blood sugar lowering effect of Tandemact:
Tandemact may either increase or weaken the effects of the following medicines:
Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and your dose of Tandemact may need to be changed.
Tandemact with alcohol Avoid alcohol while taking Tandemact since alcohol may increase or decrease the blood sugar lowering action of Tandemact in an unpredictable way.
Pregnancy and breast-feeding Do not use Tandemact if you are pregnant. You must tell your doctor if you are, you think you may be pregnant or are planning to have a baby. Your doctor will advise you to discontinue this medicine. Do not use Tandemact if you are breastfeeding or are planning to breast-feed (see section Do not take Tandemact ).
Driving and using machines Alertness and reaction time may be impaired due to low or high blood sugar due to glimepiride, especially when beginning or after altering treatment, or when Tandemact is not taken regularly. This may affect your ability to drive or use machines.
Take care if you experience abnormal vision.
Tandemact contains lactose monohydrate If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Tandemact.
Tandemact contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one tablet taken once daily shortly before or with the first main meal. Your doctor will tell you the dose to take or if necessary to change to a different dose. You should swallow the tablets with a glass of water.
If you have the impression that the effect of Tandemact is too weak, talk to your doctor.
If you are following a special diet for diabetes, you should continue with this while you are taking Tandemact.
Your weight should be checked at regular intervals; if your weight increases, inform your doctor.
Your doctor will ask you to have blood tests periodically during treatment with Tandemact.
If you take more Tandemact than you should If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. Your blood sugar could fall below the normal level. The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness, nausea, coma or convulsion. Your blood sugar level can be increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.
If you forget to take Tandemact Take Tandemact daily as prescribed. However if you miss a dose, skip the missed dose and just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten tablet.
If you stop taking Tandemact Tandemact should be used every day to work properly. If you stop using Tandemact, your blood sugar may go up. Talk to your doctor before stopping this treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In particular, patients have experienced the following serious side effects:
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact. Signs and symptoms include blood in your urine, pain when urinating or a sudden need to urinate. If you experience any of these, talk to your doctor as soon as possible.
Hypoglycaemia (low blood sugar) has been reported uncommonly (may affect up to 1 in 100 people) in patients taking Tandemact. The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea. It is important to know what symptoms to expect when hypoglycaemia (low blood sugar) occurs. Ask your doctor or pharmacist for more information if you are not sure how to recognise this and what you should do if you experience the symptoms.
Decrease in blood platelets (which increases risk of bleeding or bruising), red blood cells (which makes the skin pale and cause weakness or breathlessness) and white blood cells(which makes infections more likely) have been reported in patients taking Tandemact rarely (may affect up to 1 in 1,000 people). If you experience this side effect, talk to your doctor as soon as possible. These problems generally get better after you stop taking Tandemact.
Localised swelling (oedema) has also been experienced commonly (may affect up to 1 in 10 people) in patients taking Tandemact in combination with insulin. If you experience this side effect, talk to your doctor as soon as possible.
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Tandemact and have also been reported in male patients (frequency cannot be estimated from the available data) taking Tandemact. If you experience this side effect, talk to your doctor as soon as possible.
Blurred vision due to swelling (or fluid) at the back of the eye (macular oedema) has also been reported in patients taking Tandemact (frequency cannot be estimated from the available data). If you experience this symptom for the first time, talk to your doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Tandemact. If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor immediately.
Some patients experienced the following side effects whilst taking pioglitazone and sulphonylureas, including glimepiride:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency can not be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via waste water or household waste. Ask you pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Tandemact contains
Marketing authorisation holder CHEPLAPHARM Arzneimittel GmbH Ziegelhof 17489 Greifswald Germany
Manufacturer Takeda Ireland Limited, Bray Business Park, Kilruddery, County Wicklow, Ireland Delpharm Novara S.r.l., Via Crosa, 86, 28065 Cerano (NO), Italy Takeda GmbH, Production Site Oranienburg, Lehnitzstrasse 70 98, 16515 Oranienburg, Germany
This leaflet was last revised in 08/2023. Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Entry 1 - fullUrl = Composition/composition-en-bef5164082ea0e74f1594414cc1788ab
Resource Composition:
Generated Narrative: Composition composition-en-bef5164082ea0e74f1594414cc1788ab
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/06/366/006status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tandemact
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpbef5164082ea0e74f1594414cc1788ab
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpbef5164082ea0e74f1594414cc1788ab
identifier:
http://ema.europa.eu/identifier
/EU/1/06/366/006type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tandemact 30 mg/2 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en